FDA approval of IDVYNSO gives Merck a fresh HIV story, but will clinicians switch stable patients?
Merck’s IDVYNSO has won FDA approval in HIV. Read what the new two-drug regimen changes, where it fits, and what risks still matter.
Gilead expands its HIV playbook as lenacapavir moves from niche drug to platform strategy
Gilead’s CROI 2026 data highlight lenacapavir’s evolution into a platform for HIV treatment and prevention. Explore what this changes for clinicians and regulators.